Cargando…
Teriparatide for osteoporosis: importance of the full course
Teriparatide (TPTD) is the only currently available therapeutic agent that increases the formation of new bone tissue and can provide some remediation of the architectural defects in the osteoporotic skeleton. The use of teriparatide clinically is limited to 24 months. We review clinical findings du...
Autores principales: | Lindsay, R., Krege, J. H., Marin, F., Jin, L., Stepan, J. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947115/ https://www.ncbi.nlm.nih.gov/pubmed/26902094 http://dx.doi.org/10.1007/s00198-016-3534-6 |
Ejemplares similares
-
PINP as a biological response marker during teriparatide treatment for osteoporosis
por: Krege, J. H., et al.
Publicado: (2014) -
Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007) -
Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012) -
Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011) -
Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)